Achieve Life Sciences Adds Director Amid Board Transitions

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Achieve Life Sciences ( (ACHV) ) has issued an update. On May 11, 2026, Achieve Life Sciences appointed Christopher Martin to its board under a designation right linked to a recent private placement, granting him standard non-employee director compensation, including a pro-rated $40,000 retainer and stock options vesting over three years. The company agreed to nominate Martin for re-election at its 2026 and 2027 annual meetings while Frazier Life Sciences maintains a significant stake, signaling investors’ deeper governance role. Board changes continued with long-time director and chairman Thomas King notifying the company on May 7, 2026 that he will resign effective June 8, after which director Lucian Iancovici, MD, will assume the chair role. In a further leadership shift, Chief Commercial Officer Jaime Xinos will leave Achieve effective May 31, 2026, with severance under her employment agreement, as the company reorganizes its commercial leadership ahead of an anticipated cytisinicline launch, underscoring a broader governance and executive refresh during a critical pre-commercial phase. The most recent analyst rating on (ACHV) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Achieve Life Sciences stock, see the ACHV Stock Forecast page. Spark’s Take on ACHV Stock According to Spark, TipRanks’ AI Analyst, ACHV is a Neutral. The score is held down primarily by weak financial performance (no revenue, sizable losses, and persistent cash burn). Partially offsetting this are tangible regulatory progress and a major financing event that improves the company’s ability to fund trials and commercialization, while technical indicators remain mixed and valuation lacks profitability or dividend support. To see Spark’s full report on ACHV stock, click here. More about Achieve Life Sciences Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline, a plant-based investigational therapy for nicotine dependence. The company is targeting both smoking and vaping cessation, supported by Phase 3 data for smoking cessation and Phase 2 data in vaping, and is preparing for potential U.S. commercialization pending regulatory approval. Average Trading Volume: 1,061,851 Technical Sentiment Signal: Buy Current Market Cap: $534.9M